William Huynh

Will advises on U.S. merger control in international M&A transactions. Will also counsels clients on cartel and other antitrust conduct. Prior to joining Linklaters, Will was an attorney at the U.S. Federal Trade Commission, where he investigated mergers in a variety of industries, including pharmaceutical manufacturing and distribution, medical devices, and technology.

Representative experience

• Perfetti van Melle: advising on its US$1.35bn acquisition of Mondelez’s developed-market gum business in the United States, Canada and Europe.
• Novozymes: advising on its US$12.3bn merger with Chr. Hansen Holding.
• Novartis: advising on various transactions, including its collaboration and license agreement with BeiGene, Ltd. and acquisition of Spinifex Pharmaceuticals, Inc.
• Bayer: advising on approximately US$8bn divestiture of its animal health business to Elanco Animal Health Incorporated.
• Linde: advising on its approximately US$70bn global business combination with Praxair Inc.
• Dr. Reddy’s Laboratories: advising on its approximately US$350m acquisition of Teva/Allergan divestiture products.
  
   

Will received his Juris Doctorate in 2011 from University of Virginia School of Law. Prior to that, in 2005, he obtained his Bachelor of Arts from Cornell University.